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Introduction
Small-molecule-induced beta-cell proliferation in humans 
could be of therapeutic importance to type 1 diabetes. Type 
1 diabetes involves the autoimmune destruction of pancre-
atic beta cells, resulting in absolute dependence on injected 
insulin for survival. There is evidence that beta-cell replace-
ment can be at least temporarily therapeutic for the treat-
ment of type 1 diabetes. The Edmonton protocol for islet 
transplantation1 demonstrated that patients could achieve 
insulin independence up to about 1 year after the procedure. 
However, patients required islets from at least two donors, 
with the result that the demand for islets exceeds organ sup-
ply. Furthermore, in a follow-up study of 36 islet recipients 
treated at nine transplantation centers,2 only one-third of 
patients were insulin-independent after 2 years. These 
results demonstrate that beta-cell supplementation can 
result in insulin independence but that islet transplantation 
itself may be most appropriate for patients with very poor 
glycemic control given the limited supply of islets.
Type 1 diabetic patients with long-standing disease 
exhibit residual beta-cell mass. Meier et al.3 examined 42 
samples from type 1 diabetic donors and found that 88% of 
them had at least some beta cells, which was not correlated 
with the duration of disease. The high frequency of apopto-
sis observed suggested that the beta cells were continuing to 
regenerate. Accordingly, a later study found a 100-fold 
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Abstract
A small-molecule inducer of beta-cell proliferation in human islets represents a potential regeneration strategy for treating 
type 1 diabetes. However, the lack of suitable human beta cell lines makes such a discovery a challenge. Here, we adapted 
an islet cell culture system to high-throughput screening to identify such small molecules. We prepared microtiter plates 
containing extracellular matrix from a human bladder carcinoma cell line. Dissociated human islets were seeded onto these 
plates, cultured for up to 7 days, and assessed for proliferation by simultaneous Ki67 and C-peptide immunofluorescence. 
Importantly, this environment preserved beta-cell physiological function, as measured by glucose-stimulated insulin secretion. 
Adenoviral overexpression of cdk-6 and cyclin D1, known inducers of human beta cell proliferation, was used as a positive 
control in our assay. This induction was inhibited by cotreatment with rapamycin, an immunosuppressant often used in islet 
transplantation. We then performed a pilot screen of 1280 compounds, observing some phenotypic effects on cells. This 
high-throughput human islet cell culture method can be used to assess various aspects of beta-cell biology on a relatively 
large number of compounds.
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increase in beta-cell proliferation in an elderly patient with 
recent-onset type 1 diabetes.4 Importantly, a recent study of 
Joslin Medalists (patients with type 1 diabetes for >50 
years) showed that all postmortem pancreata contained 
some insulin-positive cells, a subset of which were also ter-
minal dUTP nick-end labeling (TUNEL)–positive and 
therefore apoptotic.5 Identification of a residual beta-cell 
population in type 1 diabetic pancreata means that these 
cells could be a potential source of new beta cells and sug-
gests that stimulation of beta-cell proliferation may be a 
feasible approach in type 1 diabetes.
Beta-cell proliferation is the primary means of beta-cell 
replacement in rodents. Seminal work in 2004 determined 
that new beta cells in the mouse arise from cell division of 
existing beta cells and not from a stem-cell population.6 It is 
unclear whether this principle applies to humans. A recent 
effort to study pancreatic samples from young human 
donors showed that replication is indeed responsible for 
beta-cell expansion after birth but that it drops off dramati-
cally to negligible levels by late adolescence.7 A follow-up 
study of beta-cell turnover by BrdU staining confirmed that 
although some replicating beta cells could be found in 
donors younger than 20 years, none were observed in 
patients older than 30 years.8 However, an analysis of 
donors between 7 and 66 years of age found cells positive 
for the proliferative marker Ki67 in every sample tested.5 
Although many reports have documented conditions to 
induce the proliferation of rodent beta cells in culture, far 
fewer have confirmed human beta-cell proliferation. Recent 
work in human islets using in vitro lineage-tracing tech-
niques detected human beta-cell proliferation in cell cul-
ture.9 In this case, however, the proliferating cells 
dedifferentiated and showed lower insulin expression, sug-
gesting that redifferentiation to a beta-cell state may be nec-
essary.10 These studies illustrate the ambiguity of whether 
adult human beta cells replicate, and they demonstrate the 
need for small-molecule probes to modulate and better 
understand this process.
Overexpression of key genes can induce human beta-cell 
proliferation. For example, overexpression of cyclin-depen-
dent kinase 6, in the presence or absence of cyclin D1, 
caused an increase in human beta cell proliferation.11,12 
Importantly, these effects also extended to in vivo models of 
islet transplantation. Similarly, overexpression of the devel-
opmental transcription factor Nkx6.1 increased beta cell 
proliferation in human islets, as measured by thymidine 
incorporation, with a preservation of insulin secretion.13 
These examples suggest that proliferation of human beta 
cells, although rare in normal adults, is inducible under the 
right conditions.
The general lack of a suitable human beta cell line14 has 
led to reliance on cadaveric donor islets for study. To enable 
identification of small molecules capable of inducing human 
beta-cell proliferation, we report here the development of a 
system to culture dissociated human islet cells, by adapting 
existing islet culture techniques to a 384-well format, for 
high-throughput screening (HTS). This cell culture method 
preserves insulin expression and secretion, and beta cells 
remain responsive to a known genetic stimulus for prolifera-
tion. We used this system to perform a pilot screen on 1280 
compounds. This cell culture system lays the groundwork for 
the identification of novel small molecules that affect human 
beta-cell biology.
Materials and Methods
Ethics Statement
The use of discarded human islet tissue for basic research 
was exempted from institutional review board approval.
Preparation of Extracellular Matrix Cell 
Culture Plates
HTB-9 human bladder carcinoma cells (American Type 
Culture Collection [ATCC], Manassas, VA) were cultured 
in 96-well and 384-well plates with 100 µL/well and 50 µL/
well, respectively, of RPMI media containing 10% fetal 
bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL 
streptomycin. We modified the methods developed by 
Beattie et al.15 to high-density cell culture. Cells were 
grown to confluence and cultured for an additional 3 days 
to allow the deposition of more extracellular matrix (ECM). 
To denude (or decellularize) the surface, in which cells are 
removed while leaving behind the intact ECM, media were 
aspirated and incubated for 6 min at 37 °C with 100 µL/
well (96) of 20 mM NH
4
OH in phosphate-buffered saline 
(PBS). The NH
4
OH was then triturated four to five times 
with a multichannel pipettor and aspirated. Plates were 
washed four to five times with fresh PBS and inspected to 
ensure that cells were removed. Denuded plates were stored 
for up to 3 weeks in a 37 °C incubator in PBS for future 
use. For 384-well plates, we used a CyBio Vario (CyBio, 
Jena, Germany) to add 50 µL/well of 20 mM NH
4
OH in 
PBS. Cultures were left at room temperature for 8 min. The 
NH
4
OH solution was triturated six times, then washed and 
triturated with fresh PBS four times, with plates stored in a 
fresh round of PBS. Plates were left hydrated in PBS to 
store for approximately 3 weeks in a 37 °C incubator.
Human Islet Cell Culture
Human islets were obtained through the Integrated Islet 
Distribution Program (IIDP; http://iidp.coh.org/), the 
National Disease Research Interchange (http://www.ndrire 
source.org/), and Beta-Pro (http://betaprollc.com). The 
purity and viability of human islets are reported to be 70% 
to 93% and 70% to 98%, respectively, and the average age 
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of cadaveric donors was 41.4 ± 11.5 years (range, 12–58 
years; n = 18). Specific data on individual donors are 
reported in Supplemental Table S1. Islets were washed 
with PBS and incubated in CMRL medium (Cellgro; 
Mediatech, Manassas, VA) supplemented with 10% FBS, 2 
mM glutamine, 100 U/mL penicillin, and 100 µg/mL strep-
tomycin. Intact islets were stored in 60-mm Petri dishes in 
a 37 °C incubator at approximately 5000 islet equivalents 
(IEQ) per 10 mL media.
Islet Dissociation
To dissociate tissue, islets were pelleted and washed in PBS 
to remove any additional media/serum that might interfere 
with dissociation process. Islets were centrifuged at 1000 
rpm for 5 min at room temperature. Pelleted islets were 
incubated at 5000 IEQ/mL in Accutase (Innovative Cell 
Technologies, San Diego, CA) at 37 °C for 20 min. The 
islet suspension was triturated five times, the dissociated 
Figure 1. Preparation of surface for islet cell culture system. (A) Human bladder carcinoma HTB-9 cells grown to confluence on 96- and 
384-well plates. Overlay of bright-field and fluorescent Hoechst nuclear dye. (B) After denuding the cells from the plate, the plate surface 
was stained for fibronectin (red) and laminin (green) levels. Scale bar = 10 µm. (C) Immunofluorescence on an intact human islet, revealing 
cellular architecture and distribution of cells. Red, insulin; green, glucagon. (D) Immunofluorescence on dissociated islet cells seeded in a 
384-well plate. Red, C-peptide; green, glucagon; blue, Hoechst nuclear dye. Scale bar = 100 µm.
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material was diluted with fresh CMRL complete media and 
centrifuged at 1000 rpm for 5 min, and supernatant was 
aspirated. The pellet was resuspended in CMRL complete 
media, and an aliquot was removed for cell counting with a 
hemacytometer. Trypan blue was used to determine viabil-
ity. We seeded 30 000 cells per well in 96-well plates (100 
µL/well) and 8000 cells per well in 384-well plates (50 µL/
well) with a Multidrop Combi automated liquid dispenser 
(Thermo Scientific, Waltham, MA).
Immunofluorescence
Cultures were fixed for 15 min at room temperature using 
freshly prepared 3% paraformaldehyde and washed twice 
with PBS. Cells were permeabilized for 20 min at room 
temperature in PBS containing 0.2% Triton-X 100 and 
blocked overnight at 4 °C with 2% bovine serum albumin 
(BSA) in PBS. We used a FITC-conjugated anti-Ki67 anti-
body. The C-peptide antibody, developed by Ole D. 
Madsen (Hagedorn Research Institute, Copenhagen, 
Denmark), was obtained from the Developmental Studies 
Hybridoma Bank developed under the auspices of the 
National Institute of Child Health and Human Development 
(NICHD) and maintained by the University of Iowa, 
Department of Biology (Iowa City, IA). Primary antibodies 
were diluted in antibody dilution buffer (ADB; 1% BSA in 
PBS) and incubated overnight at 4 °C, followed by three 
washes in ADB. Cultures were incubated in secondary anti-
body (Alexa Fluor-conjugated anti-mouse; Invitrogen, 
Carlsbad, CA) diluted in ADB for 1 h at room temperature, 
followed by five washes with PBS. Plates were stored foil-
sealed at 4 °C with 100 µL/well PBS. Plates were imaged 
with an ImageXpress Micro automated microscope 
(Molecular Devices, Sunnyvale, CA), and automated image 
analysis was performed using the Multiwavelength Cell 
Scoring Application Module in MetaXpress software 
(Molecular Devices).
Results
All cells in the body are surrounded by an ECM that pro-
vides structural support and plays a role in cell adhesion, 
migration, and differentiation. This environment can be 
re-created in vitro by a variety of methods to develop a 
more physiological cell culture system. Attachment of islet 
cells to tissue culture–treated plates has historically proven 
difficult, so reports in the literature discussed the develop-
ment of methods to deposit ECM on plates before culturing 
islets. In particular, the ECM secreted by the human HTB-9 
bladder carcinoma cell line has been shown to preserve 
beta-cell function, with glucose-stimulated insulin secre-
tion (GSIS) preserved to a large extent.15
We have developed an automated method of creating 
this optimized microenvironment in 96- and 384-well 
plates. HTB-9 cells are cultured to confluence in standard 
tissue culture–treated plates (Fig. 1A), allowing them time 
to secrete various matrix factors, such as collagen IV, lam-
inin, and fibronectin, on the surface of the plate (Fig. 1B). 
The cells are then detached from the tightly associated 
matrix by brief treatment with ammonium hydroxide, fol-
lowed by extensive washing with PBS. This method results 
in the preservation of the ECM on the surface of the plate 
(Suppl. Fig. S1), into which islet cells can be subsequently 
seeded for attachment.
To ensure that our methods preserve beta-cell function 
and identity in high-density culture, we gently dissociated 
human islets into small cell clusters and compared insulin 
and glucagon expression to that of intact islets. A fairly 
even distribution of endocrine cells was observed in the 
intact islets (Fig. 1C), consistent with an examination of the 
differences in islet cytoarchitecture between different spe-
cies.16 When we dissociated human islets and plated them in 
our system, we observed that 20% to 50% of the cells were 
C-peptide-positive beta cells, depending on the purity of the 
islet preparation (Fig. 1D). We also detected 10% to 40% 
glucagon-positive alpha cells (Fig. 1D). We moved from 
staining beta cells with an insulin antibody to a C-peptide 
antibody. C-peptide is a cleavage product of proinsulin, and 
we used this marker because of concerns that insulin pres-
ent in the media can be taken up by cells and detected incor-
rectly as beta cells. Both antibodies worked well in our 
culture system and identified the same cell population 
(Suppl. Fig. S2).
Cells remained viable for at least 7 days in culture, which 
was the maximum duration we tested (Suppl. Fig. S3). To con-
firm beta-cell function, we measured GSIS in dissociated cul-
ture. We consistently observed a stimulation index of at least 
twofold, with this value partially dependent on islet purity and 
donor body mass index (BMI). In general, the purity of the 
islet preparation was important to GSIS; above ~85% purity, 
islet cells secreted higher levels of insulin reliably (Fig. 2A). 
Most islet preparations resulted in an insulin stimulation index 
of ~2, although a few high-BMI samples showed greater insu-
lin secretion (Fig. 2B), reflecting not only the high donor-to-
donor variability we observed throughout the process but also 
the variation in islet isolation, as determination of islet purity is 
a subjective measure. Overall, these results indicate that this 
high-throughput cell culture system is capable of preserving 
beta-cell identity and function.
We observed that 5% to 10% of all islet cells are prolif-
erating, as measured by Ki67 immunofluorescence.17 
However, by morphology, the Ki67-positive cells generally 
appear to be fibroblasts (large nuclei not surrounded by 
C-peptide-positive cytoplasm) and not beta cells (small 
nuclei surrounded by C-peptide-positive cytoplasm) 
(Suppl. Fig. S4). We found that Bay K8644, a small mole-
cule reported to induce human beta-cell proliferation,18 was 
more likely increasing the proliferation of supporting cells, 
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such as fibroblasts, and not beta cells (Suppl. Fig. S5). To 
identify a positive-control condition for HTS, we infected 
dissociated islets in our culture system with adenoviruses 
encoding cdk-6 and cyclin D
1
.11,12 After 3 days of overex-
pression, we observed a visible increase in beta cell prolif-
eration (Fig. 3A). Because the cells were dissociated and 
cultured as a single layer of cells on ECM, we could clearly 
distinguish individual replicating cells and therefore could 
be certain that Ki67-positive nuclei indeed belonged to beta 
cells (Fig. 3B–E). This is not the case when identifying 
individual replicating cells within intact islets, for which 3D 
imaging is very challenging. Previous work to overexpress 
these genes in human islet cells showed that TUNEL stain-
ing was not increased.11,12 Furthermore, we observed no 
apparent visual differences in replicating beta cells; the 
morphology of replicating beta cells was similar to those 
beta cells that were healthy and quiescent, consistent with 
published reports.11,12
Figure 2. Cell culture system preserves glucose-stimulated insulin secretion (GSIS). (A) Islets from preparations with the indicated 
purity of isolation were dissociated, seeded into 96-well plates, and incubated for 1 h with either 1.67 mM (light blue bars) or 16.7 
mM (dark blue bars) glucose to assess GSIS. (B) GSIS data are plotted relative to the body mass index (BMI) of the donor and, as the 
stimulation index, relative to 1.67 mM glucose. Data represent the mean ± standard deviation of four to eight independent wells.
Figure 3. Beta cell proliferation induced by cdk-6 and cyclin D
1
 in high-density culture. (A) Dissociated islet cells were cultured on 
extracellular matrix (ECM) and infected for 24 h with adenovirus vectors encoding cdk-6 and cyclin D1, incubated for 3 days in cell 
culture, and then fixed and assessed for C-peptide (a cleavage product of proinsulin) and Ki67 expression. Cells simultaneously positive 
for Ki67 and C-peptide are indicated by white arrowheads. To ensure that individual cells positive for Ki67 were expressing C-peptide, 
higher magnification images were acquired: (B) Hoechst nuclear dye, (C) Ki67, (D) C-peptide, and (E) image overlay.
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In addition to examining the islet cells visually, we quan-
tified the number of beta cells in each well and the percent-
age of those that were also Ki67-positive. Proliferating beta 
cells increased in proportion to the total multiplicity of 
infection (MOI) used for infection, proceeding from less 
than 1% in the uninfected state (Fig. 4A, column 1) to 
nearly 30% at an MOI of 800 (Fig. 4A, column 5). These 
MOI values are consistent with previous efforts to infect 
dissociated islet cells.11,12 The low but nonzero background 
value in the uninfected state does not, in fact, represent pro-
liferating beta cells but is an artifact of the automated image 
analysis (Suppl. Fig. S6). The effects of cdk-6 and cyclin 
D
1
 appeared to be specific to beta cells, as the percentage 
of proliferation within the heterogeneous population of 
insulin-negative cells did not change with increasing MOI 
(Fig. 4B). Finally, we tested whether rapamycin or FK506 
could inhibit the proliferation induced by cdk-6 and cyclin 
D
1
. These immunosuppressants are used to treat islet trans-
plant recipients, and it has been shown that these treatments 
are deleterious to beta cells.19 We observed a strong decrease 
in the percentage of proliferating beta cells in the presence 
of 10 nM and 20 nM rapamycin but not in the presence of 
10 nM or 20 nM FK506 (Fig. 4C). These results demon-
strate that we can reliably detect beta-cell proliferation in 
this system and that this phenomenon is inhibited by 
rapamycin cotreatment.
We then sought to determine the suitability of this sys-
tem for small-molecule screening and the effects of donor 
variation on screening outcomes. This aspect is important to 
establish reproducibility and reliability during HTS. We 
screened a small collection of 1280 compounds, represent-
ing a subset of G-protein-coupled receptor (GPCR)–biased 
compounds and a subset from a structurally diverse inter-
nally synthesized library, in islet samples from three donors. 
Sixty-four DMSO wells present on each 384-well plate 
were used as vehicle controls. Comparing the control wells 
across donors, we observed that two of the samples, from 
relatively similar donors (Suppl. Table S1), were very sim-
ilar in the total number of cells per well and the percent of 
beta cells present in each well (Fig. 5A,B). However, a 
sample of islets from a very young (12 years old) donor had 
a higher percentage of beta cells in each well (Fig. 5B), 
perhaps reflecting a greater starting beta-cell mass in each 
islet.
We used the DMSO wells to calculate the averages, stan-
dard deviations, and coefficients of variation (CVs) for each 
of the parameters output by image analysis (Suppl. Table S2). 
In general, the detection of Ki67-positive cells was more 
variable than the detection of total cells. Interestingly, the 
lowest CVs were observed in parameters involving detect-
ing beta cells, either as counting the total number or as a 
percentage of each field of view (Suppl. Table S2). Again, 
there were nonzero values reported for the number of cells 
positive for all three stains, but these generally corre-
sponded to false positives, which were unavoidable with 
our current image analysis but do not affect the overall out-
come. Analysis of each compound-treated well for prolifer-
ating beta cells revealed that none of the compounds 
were positive outliers compared to the DMSO control wells 
(Fig. 5C–E) and that all compound treatments fell within 
the background of the DMSO distribution.
Each of the three pilot screens was performed in a single 
replicate. To assess intradonor reproducibility of the assay, 
we tested each donor with one compound plate in duplicate 
Figure 4. Quantification of proliferation in response to cdk-6 and cyclin D
1
. Dissociated islet cells infected for 24 h with increasing 
total multiplicity of infection (MOI) of cdk6 and cyclin D1 and incubated for 3 days were imaged and quantified for cell identity and 
proliferation status. (A) The percentage of proliferating C-peptide-expressing beta cells was quantified in each well of a 96-well plate. (B) 
The percentage of proliferating C-peptide-negative cells (including other islet endocrine cell types, endothelial cells, and fibroblasts) was 
quantified in each well of a 96-well plate. (C) Islet cells were infected with cdk-6 and cyclin D1 at an MOI of 200 for each gene in the 
absence or presence of indicated concentrations of the immunosuppressants rapamycin, FK506, or both. After a 3-day incubation, cells 
were fixed, stained, and quantified in the same manner as above. Data represent the mean ± standard deviations of 32 independent wells.
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and analyzed the compound treatments within several per-
well statistics. There was quite a bit of variability in the 
donors (Suppl. Fig. S7). In one donor sample, we observed 
that some measurements had modest reproducibility, such 
as total number of cells (Fig. 6A; R2 = 0.31), number of 
proliferating insulin-negative cells (Fig. 6B; R2 = 0.48), and 
number of quiescent beta cells (Fig. 6C; R2 = 0.39). 
However, the number of proliferating beta cells was essen-
tially random (Fig. 6D; R2 = 0.03). Knowing that these 
compounds have no effect on beta-cell proliferation, it was 
not particularly surprising that these measurements, all 
essentially within the noise of the assay, do not reliably 
reproduce. This islet sample was high purity (90%) and 
from a donor with relatively average biometrics (Suppl. 
Table S1), suggesting that these biometrics might best be 
optimized for screening.
Discussion
To identify small molecules capable of inducing human 
beta-cell proliferation, we needed an in vitro system in 
which dissociated human islet cells can be maintained in 
culture for HTS. Human beta cells do not proliferate as 
readily as rat or mouse cells, so results obtained using 
rodent cell lines would presumably not translate well to 
human cells. Furthermore, the lack of suitable human beta 
cell lines14 for high-throughput culture necessitates the use 
of primary tissue. To achieve this goal, we adapted a culture 
method using the ECM secreted by the human HTB-9 blad-
der carcinoma cell line (Fig. 1).15 Dissociated islet cells 
cultured on ECM remained viable for at least 7 days in 
culture. To confirm beta-cell function, we measured GSIS 
in dissociated culture (Fig. 2); our results show that the 
Figure 5. Pilot screen of 1280 compounds across three batches of islets. Islets from three organ donors were dissociated and cells 
seeded into extracellular matrix (ECM)–prepared 384-well plates. Cells were treated with individual members of a small-molecule 
collection, one compound per well, and incubated for 3 days. (A) Histogram of total cells per well across the three samples. (B) Histogram 
of the percentage of C-peptide-positive beta cells per well across the three samples. (C–E) Screening outcomes. The absolute number of 
proliferating beta cells was quantified in each well. Data are represented as box-whisker plots summarizing the wells of each compound 
plate (“1–4”) and all DMSO control wells across the plates (“DMSO wells,” boxed in pink). For the box-whisker plots, the mean value of 
the data set is represented by the central line of the box and the median by “+.” The box size represents the 25th and 75th percentiles 
of the data and the whiskers the 1st and 99th percentiles. Further outliers are represented by dots. Graphical schematic is shown. Box-
whisker plots of screening outcomes for (C) donor 1, (D) donor 2, and (E) donor 3.
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dissociated islet cells not only express insulin protein but 
also secrete it in a glucose-dependent manner.
Human pancreatic islets require specific culture conditions 
in terms of media composition and supplements,10,20,21 but it is 
becoming increasingly clear that the preservation of beta-cell 
function also requires the maintenance of interactions between 
beta cells and the ECM.22,23 These interactions have important 
roles in regulating cell survival,24 insulin secretion,25 and pro-
liferation.26 The peripheral ECM of mature human islets is 
composed essentially of laminin and collagen IV,27 although 
fibronectin and collagens III, V, and VI have been also 
reported.23,28 It is possible that the laminin component of the 
ECM from the HTB-9 cell line is more similar to that of intact 
islets in vivo and is thus conducive to beta cell attachment and 
function. In vitro adhesion studies, for example, show that 
human beta cells adhere well to surfaces coated with purified 
laminin-511.29 Human islet isolation leads to a loss of the ECM 
that can contribute to eventual apoptosis and dedifferentiation 
in vitro. We believe that one advantage of our cell culture sys-
tem is that it may more faithfully replicate the physiological 
conditions of the human pancreas.
We used adenoviral overexpression of cdk-6 and cyclin 
D
1
 as a positive control to induce beta-cell proliferation 
(Fig. 3). These conditions were previously used to demonstrate 
Figure 6. Analysis of screening performance reproducibility. Islet cells were dissociated and treated for 3 days in duplicate with 1280 
compounds. The two replicates are plotted against each other examining (A) total cells, (B) proliferating C-peptide-negative cells, (C) 
quiescent C-peptide-positive beta cells, and (D) proliferating beta cells. The correlations of each data set to a linear fit are shown.
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the importance of modulating cell-cycle activity in beta 
cells.11 Although this treatment would not be suitable thera-
peutically, our results confirm the ability of the assay to 
detect beta-cell proliferation under these conditions. We also 
show that this induced proliferation is inhibited by cotreat-
ment with 10 nM rapamycin (Fig. 4), consistent with a report 
showing impairment of beta-cell regeneration in mice by a 
combination of rapamycin and FK506.19 Rapamycin and 
FK506 are immunosuppressive drugs used in organ trans-
plants to prevent rejection of islet transplants, but these 
drugs are deleterious to beta cells. Interestingly, we observed 
that rapamycin inhibited proliferation to a much greater 
extent than FK506. An intriguing use of this cell culture sys-
tem involves testing novel immunosuppressants for their 
effects on beta-cell proliferation. Because human islet trans-
plantation for the treatment of type 1 diabetes is accompa-
nied by immunosuppressant therapy, the identification of 
new therapies that spare beta cells would represent a clini-
cally important advance.
We performed a pilot screen of 1280 compounds across 
three donor islet samples (Fig. 5). We found that the vari-
ability of readouts was lowest for all three donors in the 
detection of numbers of beta cells per well. Furthermore, 
we observed that reproducibility of readouts was greater in 
the donor in which biometrics were more average (age, 
BMI) than others (Fig. 6). We did observe high donor-to-
donor variation, even among donors with similar islet 
purity and/or BMI. Given the rarity of proliferating beta 
cells, larger scale screening with replicate donors will be 
necessary to increase the opportunity to identify small mol-
ecules with this activity, and additional statistical modeling 
of rare events will be appropriate to such screens. Our 
results validate this cell culture system and indicate that it 
is a practical and useful system for HTS of human islet 
cells.
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